Thursday, 25 Apr 2019

You are here

Risk of Psoriasis Complicating TNF Inhibitor Therapy

A population-based study of claims data from Korea shows that among inflammatory bowel disease (IBD) patients receiving tumour necrosis factor inhibitors (TNFi) there is a 3.7 per 100 patient-year risk of paradoxically developing psoriasis - a rate that is roughly 3-fold higher than risk in TNFi-naive IBD patients.

Using the Korea National Health Insurance Claim Data between 2007 and 2016, investigators examined all IBD patients (n = 50,502) to compare 5428 TNFi treated patients with 10,856 matched controls who were TNFI naive. Key findings include:

  • TNFi patient have increased risk for psoriasis - 36.8 per 10 000 person-years compared to the control group (14.5 per 10 000 person-years) (hazard ratio [HR] 2.357, 95% CI: 1.668-3.331).
  • TNFi treated patients also showed a higher risk of Palmoplantar pustulosis (HR 9.355, 95% CI 2.754-31.780) and psoriatic arthritis (HR 2.926, 95% CI 1.640-5.218)
  • Psoriasis risk was roughly the same in Crohn's disease and ulcerative colitis. 
  • The risk for psoriasiform complications was significant for infliximab (psoriasis: HR 2.6, 95% CI 1.8-3.6; palmoplantar pustulosis: HR 9.5, 95% CI 2.8-32.6,; psoriatic arthritis: HR 3.3, 95% CI 1.8-5.8), but nor for adalimumab.
  • Men and younger (10-39 years) patients have significantly higher risks of palmoplantar pustulosis (HR 19.682 [95% CI 3.867-100.169] and HR 14.318 [95% CI 2.915-70.315], respectively).

Mechanisms underlying paradoxical psoriasis are unclear but has been postulated to be due TNFi induction of interferon-a (IFN-a), activation of Th1 and Th17 cells or increased interleukin-10 production.

Psoriasiform diseases may complicate TNFi therapy with the risk of palmoplantar pustulosis being greater in male and younger patients.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

FDA Approves Cimzia for Non-Radiographic Axial Spondyloarthritis

The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called non-radiographic axial spondyloarthritis (nr-axSpA), with objective signs of inflammation. This is the first time that the FDA has approved a treatment for nr-axSpA.

Lower TNF Inhibitor Persistence in Spondylitis

A claims data analysis shows that only one-third of ankylosing spondylitis (AS) treated with tumor necrosis factor inhibitors (TNFi) therapy remain on their initial drug in the 2 years post initiation.

The Risk of Tuberculosis with TNF Inhibitors

A study from Turkey shows that among 2117 patients treated with a TNF inhibitor (TNFi) the risk of developing TB was 6 fold higher in those treated with a TNFi compared to non-users.

This retrospective cohort study included patients with rheumatoid arthritis (RA), ankylosing spondylitis, juvenile idiopathic arthritis or psoriatic arthritis (PsA) that treated with or without TNFI. The calculated the 2-year RR of TB after TNFi.

Higher Infection Rates for Infliximab in Psoriasis

A prospective study of psoriasis patients from the British Association of Dermatologists Biologic Interventions Register demonstrated that infliximab therapy yielded 2-3 times more serious infection than seen in those treated with non-biologic DMARDs or methotrexate (MTX).

Biomarker Combo Predicts TNF Inhibitor Responses

Based on clinical trial data, patients starting tumour necrosis factor-alpha inhibitors (TNFi) have roughly a two-thirds chance of achieiving a good clinical response. French investigators have studied a series of potential biomarkers and surmised that the combination of baseline prealbumin, platelet factor 4 and S100A12 can predict a 78% response to TNFi in rheumatoid arthritis (RA) patients.